Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

SSGXXII : Three versus five years of adjuvant Imatinib as treatment for patients with operable gastrointestinal stromal tumour (GIST) with a high risk for recurrence: SSGXXII: A Randomised phase III study

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

Sarcoma<br/>CancersCancer LocationSarcoma
Cancers

Systemic therapy | SarcomaGastrointestinal stromal tumors (GISTs)

Trial Overview Read MoreRead more

This phase III study is comparing the effects of 3 years versus 5 years of treatment with a targeted cancer drug (imatinib) in people with gastrointestinal stromal tumours (GIST).
 

This trial is treating patients with gastrointestinal stromal tumours (GIST).

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Three versus five years of adjuvant Imatinib as treatment for patients with operable gastrointestinal stromal tumour (GIST) with a high risk for recurrence: SSGXXII: A Randomised phase III study

Cooperative Group

Australasian Gastro-Intestinal Trials Group (AGITG)

Other Non-Commercial Sponsor

University of Sydney

Summary

To be eligible for this study you must be at least 18 years old, have been diagnosed with gastrointestinal stromal tumour (GIST), and have been treated with adjuvant imatinib for 3 years after previously having surgery. Eligible participants will be enrolled and randomly assigned to either continue to receive imatinib oral tablets (400mg/day) for 2 years, or to receive no further imatinib treatment.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Monc C Co-Team Leads
PCCTU.MoncC@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next